1. Home
  2. OMER vs CYD Comparison

OMER vs CYD Comparison

Compare OMER & CYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Omeros Corporation

OMER

Omeros Corporation

N/A

Current Price

$13.29

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Logo China Yuchai International Limited

CYD

China Yuchai International Limited

N/A

Current Price

$19.78

Market Cap

1.3B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
OMER
CYD
Founded
1994
1951
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2008
1998

Fundamental Metrics

Financial Performance
Metric
OMER
CYD
Price
$13.29
$19.78
Analyst Decision
Buy
Strong Buy
Analyst Count
3
3
Target Price
$27.50
★ $47.94
AVG Volume (30 Days)
★ 1.2M
149.2K
Earning Date
11-16-2026
08-07-2026
Dividend Yield
N/A
★ 4.07%
EPS Growth
★ 98.15
N/A
EPS
★ 0.13
N/A
Revenue
★ $29,868,000.00
N/A
Revenue This Year
N/A
$13.32
Revenue Next Year
$66.13
$8.59
P/E Ratio
$107.77
★ $32.71
Revenue Growth
N/A
★ N/A
52 Week Low
$6.70
$19.74
52 Week High
$21.24
$61.48

Technical Indicators

Market Signals
Indicator
OMER
CYD
Relative Strength Index (RSI) 30.78 30.47
Support Level $9.45 $19.74
Resistance Level $19.68 $35.66
Average True Range (ATR) 0.92 1.09
MACD -0.45 0.34
Stochastic Oscillator 8.90 2.59

Price Performance

Historical Comparison
OMER
CYD

About OMER Omeros Corporation

Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.

About CYD China Yuchai International Limited

China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.

Share on Social Networks: